Private French biotechnology company pioneering next-generation immuno-oncology therapies, focused on ICT01, a first-in-class monoclonal antibody targeting BTN3A for AML and other cancers.
Industries
Frequently Asked Questions
What industries does ImCheck Therapeutics operate in?
ImCheck Therapeutics operates in the following industries: biotechnology, immuno-oncology, pharmaceuticals.
When was ImCheck Therapeutics founded?
ImCheck Therapeutics was founded on 2025-10-22.